1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Mexco Energy Corporation reported results for the fiscal year ended March 31, 2026, in a June 29, 2026 news release furnished under Item 2.02. Net income fell 24% from fiscal 2025 and operating revenues fell 8%, which the company attributed mainly to lower average realized oil prices and reduced oil production volumes.
Net income of $1,305,722, or $0.64 per diluted share, down 24% from fiscal 2025
Operating revenues of $6,561,324, down 8%, driven by lower oil prices and reduced oil production
Cash on hand of approximately $1.4 million and no outstanding debt under the bank line of credit
Company expects to participate in 33 horizontal wells in fiscal 2027, at an estimated aggregate cost of approximately $1.8 million
BriaPro Therapeutics, a subsidiary of BriaCell Therapeutics, filed unaudited financial statements for the three and nine months ended April 30, 2026, with Canadian regulators. The nine-month net loss rose to $712,236 from $519,804 a year earlier, and the filing states a material uncertainty about the company's ability to continue as a going concern, with BriaCell as its only stated financing source until it raises more capital.
Nine-month net loss of $712,236 versus $519,804 for the same period a year earlier; three-month net loss narrowed to $240,005 from $286,619
Cash of $299,950 at April 30, 2026, including a $300,000 related-party advance from BriaCell; negative working capital of $1,937,495
Amounts owed to BriaCell group companies totaled $2,093,345; the monthly service fee was reduced from $20,000 to $5,000 effective April 30, 2026
On March 31, 2026, the company acquired the sCD80 license from BriaCell for 23,972,589 common shares valued at $846,532
KB Home reported second-quarter results for the three months ended May 31, 2026, with revenues down 27% from a year earlier to $1.11 billion and net income falling to $27.3 million from $107.9 million. Diluted earnings per share were $0.43 versus $1.50, and the homebuilding operating income margin dropped to 2.5% from 8.6%. Management said results met or exceeded the midpoint of its key guidance ranges, and the company issued third-quarter and full-year 2026 guidance and repurchased $75.0 million of common stock in the quarter.
Revenues were $1.11 billion, down 27%; homes delivered fell 23% to 2,395.
Net income was $27.3 million versus $107.9 million; diluted EPS was $0.43 versus $1.50.
Housing gross profit margin was 15.2% versus 19.3%, reflecting price reductions and higher relative land costs.
Third-quarter guidance calls for 2,600 to 2,800 deliveries; full-year housing revenues are guided to $4.90 billion to $5.30 billion.
Gencor reported second-quarter fiscal 2026 net revenue of $33.8 million, down from $38.2 million a year earlier, and net income of $3.8 million, or $0.26 per share, down 37.0% from $6.1 million, or $0.42 per share. The company attributed the decline mainly to $3.5 million of trade show expenses, compared with $345,000 a year earlier, and to lower contract equipment revenue from the timing of orders and shipments.
Net revenue for the quarter ended March 31, 2026 was $33.8 million, versus $38.2 million a year earlier.
Operating income fell 34.6% to $4.2 million, and operating margin was 12.5% versus 17.0%.
Gross profit margin rose 200 basis points to 31.7%, while backlog reached $60.5 million at March 31, 2026, versus $27.8 million a year earlier.
At March 31, 2026, Gencor had $155.1 million in cash, cash equivalents and marketable securities and no short-term or long-term debt.
Lennar reported second-quarter 2026 net earnings of $305 million, or $1.24 per diluted share, down from $477 million, or $1.81 per share, a year earlier. The company also moderated its full-year 2026 delivery target to approximately 82,000 to 83,000 homes, citing pressure on interest rates and geopolitical uncertainty.
Q2 2026 total revenues were $7.9 billion, compared with $8.4 billion in Q2 2025
Deliveries rose 2% year over year to 20,519 homes, while new orders fell 4% to 21,749 homes
Full-year 2026 delivery target moderated to approximately 82,000 to 83,000 homes
Third-quarter 2026 guidance: 20,500 to 21,500 deliveries and gross margin of approximately 16%
Lovesac reported first quarter fiscal 2027 results for the period ended May 3, 2026, with net sales of $138.2 million, down 0.1% from $138.4 million a year earlier. The net loss widened to $11.1 million, or $0.76 per share, from $10.8 million, or $0.73 per share, as gross margin fell to 52.1% from 53.7%. The company also gave fiscal 2027 and second quarter outlooks that include an expected $3.6 million tariff refund.
Q1 net sales $138.2 million vs. $138.4 million a year earlier; omni-channel comparable net sales fell 1.0%.
Net loss $11.1 million, or $(0.76) per share, vs. $10.8 million, or $(0.73) per share, a year earlier.
Adjusted EBITDA loss of $10.5 million vs. $8.4 million loss a year earlier.
Fiscal 2027 outlook: net sales $700 million to $740 million; net income $5 million to $12 million; diluted EPS $0.34 to $0.81. Q2 net loss expected at $3 million to $7 million.
J.Jill reported first quarter fiscal 2026 results with net sales down 6.0% to $144.4 million and diluted EPS of $0.31, versus $0.76 a year earlier. The company reaffirmed its full-year sales and Adjusted EBITDA outlook while guiding second-quarter net sales down 1% to 3% and Adjusted EBITDA of $18 million to $20 million.
Net sales $144.4 million, down 6.0%; total comparable sales down 8.7%
Net income $4.7 million vs. $11.7 million; diluted EPS $0.31 vs. $0.76
Adjusted EBITDA $16.7 million vs. $27.3 million; about $4.7 million of incremental net tariff costs
Q2 outlook: Adjusted EBITDA $18 million to $20 million; full-year Adjusted EBITDA $70 million to $75 million reaffirmed
Campbell's reported third-quarter fiscal 2026 net sales of $2.4 billion, down 4% on both a reported and organic basis, and adjusted EPS of $0.50, down 32% from $0.73. GAAP EPS rose to $0.41 from $0.22, largely because the prior-year quarter included a $150 million impairment charge. The company reaffirmed its full-year fiscal 2026 guidance for organic net sales, Adjusted EBIT and Adjusted EPS, so shareholders see weaker underlying profit this quarter but no change to the outlook.
Net sales were $2,366 million versus $2,475 million a year earlier, a 4% decline, with volume/mix down 5% and net price realization up 1%.
Adjusted gross profit margin fell 240 basis points to 27.7%, driven mainly by cost inflation, supply chain costs and tariffs.
Full-year fiscal 2026 guidance was reaffirmed: Adjusted EPS of $2.15 to $2.25, a 23% to 26% decline from fiscal 2025.
Cash flow from operations for the nine months was $839 million, compared with $872 million a year earlier; the company paid $380 million to shareholders year-to-date, mainly through dividends.
Seaport Therapeutics reported first-quarter 2026 results showing a net loss of $25.4 million, up from $13.1 million a year earlier, as research and development expenses roughly doubled to $21.4 million. The company had $212.6 million in cash, cash equivalents and investments at March 31, 2026, and said a May 2026 IPO that raised $260.0 million gross should fund operations into 2029, which matters to shareholders because the larger loss and new share issuance both bear on the company's cash runway and per-share results.
Net loss was $25.4 million for Q1 2026 versus $13.1 million for Q1 2025; net loss per share was $10.34 versus $5.65.
R&D expenses were $21.4 million versus $10.5 million, mainly from clinical development of GlyphAllo and GlyphAgo; G&A expenses were $6.1 million versus $5.7 million.
Cash, cash equivalents and investments were $212.6 million at March 31, 2026; the IPO closed in May 2026 with $260.0 million in gross proceeds.
Sharon Mates was appointed to the Board of Directors; Robert Nelson, Eric Elenko and Robert Lyne left the board in connection with the IPO.
Torrid Holdings reported first quarter fiscal 2026 results for the period ended May 2, 2026, with net sales down 7.6% to $245.8 million and net income falling to $0.4 million, or $0.00 per share, from $5.9 million a year earlier. The company also issued second quarter and full year fiscal 2026 outlook, and said its quarterly net sales came in slightly above its guidance. For shareholders, the sharp drop in profit and adjusted EBITDA shows weaker earnings than the prior year, and the company's outlook points to lower second quarter sales and EBITDA than the first quarter.
Net sales fell 7.6% to $245.8 million from $266.0 million; comparable sales decreased 1.7%.
Net income was $0.4 million, or $0.00 per share, versus $5.9 million, or $0.06 per share, a year earlier.
Adjusted EBITDA was $17.6 million, or 7.2% of net sales, versus $27.1 million, or 10.2%, a year earlier.
Full year fiscal 2026 outlook: net sales of $940 million to $960 million and adjusted EBITDA of $65 million to $75 million.
Virco Mfg. Corporation reported a first-quarter net loss of $2.8 million for the quarter ended April 30, 2026, compared with net income of $0.7 million a year earlier, as net sales fell 9.1% to $30.7 million. The company said the decline reflects lower shipments after the prior year's backlog overhang ended, and it declared a $0.025 per share quarterly dividend.
Net sales were $30.7 million, down 9.1% from $33.8 million a year earlier.
Net loss was $2.8 million, or $0.18 per share, versus net income of $0.7 million, or $0.05 per share, last year.
Gross margin declined to 41.4% from 47.5%.
Quarterly dividend of $0.025 per share is payable July 10, 2026 to holders of record as of June 19, 2026.
U.S. Global Investors said its earnings per share for the three and nine months ended March 31, 2026 were overstated because a spreadsheet formula omitted a component of shares from the weighted-average share count. The company will file a Form 10-Q/A, and earlier reports for those periods should no longer be relied upon, though net income, revenues, and cash flows were not affected. Management also concluded that a material weakness in internal control over financial reporting existed as of March 31, 2026.
The restatement covers the three and nine months ended March 31, 2026, previously reported in the Form 10-Q filed May 13, 2026.
Weighted-average shares were understated by 702,484 for the quarter and 230,743 for the nine months, overstating EPS by $0.02 and $0.01, respectively.
Corrected basic and diluted EPS for the quarter is $0.21; net income for the quarter was $2.7 million, which the company says is unchanged.
The Audit Committee discussed the matters with Grant Thornton LLP, and management is implementing enhanced review procedures and spreadsheet controls.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.